Cargando…

CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action

Targeting the androgen receptor (AR) signalling pathway remains the main therapeutic option for advanced prostate cancer. However, resistance to AR‐targeting inhibitors represents a great challenge, highlighting the need for new therapies. Activation of the PI3K/AKT pathway and increased expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Cheng, Xia, Hongyan, Bai, Shanshan, Zhao, Jianlei, Edwards, Holly, Li, Xinyu, Yang, Yanrong, Lyu, Jing, Wang, Guan, Zhan, Yang, Dong, Yan, Ge, Yubin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339177/ https://www.ncbi.nlm.nih.gov/pubmed/32459381 http://dx.doi.org/10.1111/jcmm.15281

Ejemplares similares

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2020)

Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth
por: Chilamakuri, Rameswari, et al.
Publicado: (2022)

Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic
por: Al-Mansour, Fares, et al.
Publicado: (2023)

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2019)

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2020)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021)

Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis
por: Zhang, Wentian, et al.
Publicado: (2020)

CUDC-907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2
por: Tu, Tian, et al.
Publicado: (2019)

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2021)

Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer
por: Jian, Zheng, et al.
Publicado: (2022)

CUDC‐907 blocks multiple pro‐survival signals and abrogates microenvironment protection in CLL
por: Chen, Yixiang, et al.
Publicado: (2018)

Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening
por: Liao, Wei, et al.
Publicado: (2021)

CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells
por: Huegel, Julianne, et al.
Publicado: (2022)

Enhanced Efficacy of 5-Fluorouracil in Combination with a Dual Histone Deacetylase and Phosphatidylinositide 3-Kinase Inhibitor (CUDC-907) in Colorectal Cancer Cells
por: Hamam, Rimi, et al.
Publicado: (2017)

Pluripotent stem cell‐based screening identifies CUDC‐907 as an effective compound for restoring the in vitro phenotype of Nakajo‐Nishimura syndrome
por: Kase, Naoya, et al.
Publicado: (2020)

Correction to: Pluripotent Stem Cell-Based Screening Identifies CUDC-907 as an Effective Compound for Restoring the In Vitro Phenotype of Nakajo-Nishimura Syndrome
Publicado: (2022)

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors
por: Grand-Guillaume, Joana, et al.
Publicado: (2023)

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
por: Oki, Yasuhiro, et al.
Publicado: (2017)

Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
por: Moertl, Simone, et al.
Publicado: (2019)

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2015)

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2016)

DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
por: Dan, Huimin, et al.
Publicado: (2019)

CUDC-101 is a potential target inhibitor for the EGFR-overexpression bladder cancer cells
por: Wang, Zhenxing, et al.
Publicado: (2023)

Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity
por: Chougule, Anuradha, et al.
Publicado: (2013)

907. Age-stratified seroprevalence of respiratory syncytial virus in Korean population
por: Nham, Eliel, et al.
Publicado: (2023)

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer
por: Ning, Changwen, et al.
Publicado: (2017)

MON-907 Silent Presentation of Urinary Bladder Paraganglioma: A Case Report
por: Kirupakaran, Johnathan, et al.
Publicado: (2020)

Antitumour Antibiotics
por: Fox, B. W.
Publicado: (1979)

Re‐evaluation of name of hydrogenated poly‐1‐decene (E 907) as food additive
por: Younes, Maged, et al.
Publicado: (2020)

Direct Stimulatory Effects of the CB(2) Ligand JTE 907 in Human and Mouse Islets
por: Ruz-Maldonado, Inmaculada, et al.
Publicado: (2021)

Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization
por: Mahale, S, et al.
Publicado: (2015)

Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer
por: Guerra, Fabiana Sélos, et al.
Publicado: (2021)

Enhanced Energy Conversion of Z907-Based Solar Cells by Cucurbit[7]uril Macrocycles
por: Al-Dmour, Hmoud, et al.
Publicado: (2019)

Antitumour activity of peroxidases.
por: Everse, K. E., et al.
Publicado: (1985)

The antitumour activities of statins
por: Takahashi, H.K., et al.
Publicado: (2007)

SUN-907 Dual Ectopic Gastrin and ACTH Secretion Leading to Combined Zollinger-Ellison Syndrome and Cushing’s Syndrome in a Patient with Metastatic Neuroendocrine Pancreatic Tumor
por: Kwak, Leigh, et al.
Publicado: (2020)

Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
por: Zhou, Maojun, et al.
Publicado: (2021)

MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
por: Chen, Jasmine, et al.
Publicado: (2023)

Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases
por: Kruczynski, A, et al.
Publicado: (2000)

907. Technology and Medicine: Prediction of Surgical Site Infection in Clean Surgeries using Artificial Neural Networks
por: de Souza, Flávio Henrique Batista, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pcrrdcrid07kng0m7gktmnr3ka